FinscoFinsco

Corcept Therapeutics (US.CORT)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CORT · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion83.7%↓
ROE1.6%↓
Cash Conversion152.2%↑
D/E Ratio0.01↓
Gross Margin98.4%→
US.CORT (Corcept Therapeutics) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    83.7%    ↓
ROE                1.6%    ↓
Cash Conversion  152.2%    ↑
D/E Ratio          0.01    ↓
Gross Margin      98.4%    →
Key Metrics
US.CORT (Corcept Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 83.7% ↓
ROE 1.6% ↓
Cash Conversion 152.2% ↑
D/E Ratio 0.01 ↓
Gross Margin 98.4% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies